

- 14 -

## REMARKS

Introductory Matters

Claims 1-27 are pending in this application. Claims 1-27 stand rejected. Applicants have amended claims 1-6 and 21.

Specifically, applicants have amended claims 1-6 to no longer encompass compounds wherein  $R^y$  is hydrogen. Applicants have made this amendment by changing "T- $R^3$ " to "T- $R^8$ " in the definition of  $R^y$  (to distinguish the  $R^3$  in T- $R^3$  from other  $R^3$  groups). Then, applicants have incorporated the definition of R into the definition of  $R^8$ , except omitting "hydrogen" from the R definition.

Applicants have amended claim 21 to delete "Alzheimer's disease."

These amendments add no new matter.

The Office Action35 U.S.C. § 112, first paragraph

Claims 11-27 stand rejected under 35 U.S.C. § 112, first paragraph as lacking enablement. The Examiner contends that the specification "while being enabling for the treatment of colon cancer, does not reasonably provide enablement for the treatment of all other diseases embraced by the instant claims." Applicants traverse.

Applicants disagree that claims 11-27 lack enablement. Nevertheless, to expedite prosecution, applicants have amended claim 21 to delete "Alzheimer's disease." Accordingly, applicants request that the Examiner withdraw these § 112 rejections.

35 U.S.C. § 102

Claims 1-5 and 9-27 stand rejected under 35 U.S.C. § 102(a) as being anticipated by Armistead et al., WO 01/60816

- 15 -

(published August 23, 2001) and as being anticipated by Pease et al., WO 01/64655 (published September 7, 2001). Claims 1-5 and 9-27 also stand rejected under 35 U.S.C. § 102(b) as being anticipated by Bradbury et al., WO 00/39101 (published July 6, 2000). Applicants traverse.

All of the WO 01/60816, WO 01/64655, and WO 00/39101 compounds have hydrogens at the position corresponding to R<sup>y</sup>. These documents, therefore, do not anticipate applicants' amended claims. Accordingly, applicants request that the Examiner withdraw these § 102 rejections.

35 U.S.C. § 103

Claims 1-5 and 9-27 stand rejected under 35 U.S.C. § 103 as being obvious over Bradbury et al., WO 00/39101. Applicants traverse.

All of the compounds of WO 00/39101 have a hydrogen at the 6-position of a pyrimidine ring (at the position corresponding to R<sup>y</sup>). In WO 00/39101, this pyrimidine ring is sterically crowded. Each substitutable position, the 2, 4, and 5-positions, are already substituted. It would not have been obvious to a skilled practitioner that a further substituent at the 6-position would have led to applicants' kinase inhibitors. Applicants' claims all call for a non-hydrogen substituent at the 6-position.


For all of the above reasons, applicants request that the Examiner withdraw these § 103 rejections.

- 16 -

Conclusion

Accordingly, applicants request that the Examiner enter the above amendments, consider the foregoing remarks, and allow the pending claims to issue.

Respectfully submitted,



\_\_\_\_\_  
Lisa A. Dixon  
Registration No. 40,995  
Attorney for Applicants  
VERTEX PHARMACEUTICALS INCORPORATED  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Telephone: (617) 444-6100  
Facsimile: (617) 444-6438